Research programme: micelle nanoparticle therapeutics - NanoCarrier

Drug Profile

Research programme: micelle nanoparticle therapeutics - NanoCarrier

Alternative Names: Docetaxel micelle; Medicelle®; protein micelle; Sensor linked micelle; siRNA micelle

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoCarrier
  • Developer JCR Pharmaceuticals; NanoCarrier
  • Class Antibodies; Boronic acids; Polymers; Proteins; Pyrazines; Small interfering RNA; Small molecules; Taxanes
  • Mechanism of Action Apoptosis stimulants; Biological factor modulators; Immunomodulators; Mitosis inhibitors; Proteasome inhibitors; RNA interference; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Brain disorders; Cancer; Haemophilia; Unspecified

Most Recent Events

  • 13 Oct 2017 NanoCarrier and JCR Pharmaceuticals conclude a collaborative research agreement for drug delivery to the brain for nucleic acid medicines for Brain disorders
  • 10 Oct 2017 Early research in Brain disorders in Japan (unspecified route)
  • 22 Dec 2014 Early research is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top